How are energy investors positioned?
Investing.com -- Telomir Pharmaceuticals Inc (NASDAQ:TELO) stock jumped 15% after the preclinical-stage biotechnology company announced new results showing its lead compound restored mitochondrial function in cells from a patient with Hutchinson-Gilford Progeria Syndrome (HGPS).
The company’s compound, Telomir-1, demonstrated the ability to restore energy in diseased cells without triggering oxidative stress or cell proliferation. The study, conducted in collaboration with Smart Assays Biotechnologies Ltd., used a Progeria human fibroblast cell line that models mitochondrial dysfunction and premature aging associated with the rare genetic disorder.
Key findings showed Telomir-1 significantly increased mitochondrial energy production while reducing reactive oxygen species under both basal and stress conditions. Importantly, the compound did not increase the number of live cells, suggesting it restored energy without triggering cell division - a potential safety advantage in genetically damaged cells.
"This cell line-specific metabolic response may reflect selective engagement of mitochondrial pathways-an encouraging signal for therapeutic programs targeting neurodegenerative diseases where mitochondrial dysfunction drives progression," said Dr. Raphael Mayer, CEO of Smart Assays.
The company believes Telomir-1’s mechanism may have broader applications across diseases where mitochondrial failure plays a central role, including Parkinson’s disease, ALS, and Alzheimer’s disease. Telomir has completed multiple preclinical studies and is finalizing IND-enabling work for Telomir-1.
"We’re now focused on selecting the right disease target that aligns with our mechanism and allows us to deliver the greatest clinical impact," said Erez Aminov, CEO of Telomir.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.